Stock Market News

Guggenheim reiterates buy rating on Larimar stock citing FDA path clarity

Jun 25, 2025 - 12:06
 0
Guggenheim reiterates buy rating on Larimar stock citing FDA path clarity
Read More

Tags:

Previous Article

Novartis: A SWAN Worth Owning

Next Article

FedEx stock price target lowered to $269 by TD Cowen on weak outlook

Related Posts

Jyong Biotech Ltd. IPO opens at $15 after pricing at $7.50 per share

Jyong Biotech Ltd. IPO opens at $15 after pricing at $7...

Jun 17, 2025  0

Southwest Airlines files for permit to fly more international routes

Southwest Airlines files for permit to fly more interna...

May 13, 2025  0

Wells Fargo stock rises after Fed lifts growth restrictions

Wells Fargo stock rises after Fed lifts growth restrict...

Jun 3, 2025  0